

Challenges associated with access to recently developed hemophilia treatments in routine care: perspectives of healthcare professionals

by Karin Berger, Roxy H. O'Rourke, Matteo Nicola Dario Di Minno, Angelika Batorova, Kaan Kavakli, Pier Mannuccio Mannucci, Wolfgang Schramm, Rhonda L. Bohn, and Louis Aledort

Received: April 15, 2024.

Accepted: November 5, 2024.

Citation: Karin Berger, Roxy H. O'Rourke, Matteo Nicola Dario Di Minno, Angelika Batorova, Kaan Kavakli, Pier Mannuccio Mannucci, Wolfgang Schramm, Rhonda L. Bohn, and Louis Aledort. Challenges associated with access to recently developed hemophilia treatments in routine care: perspectives of healthcare professionals.

Haematologica. 2024 Nov 14. doi: 10.3324/haematol.2024.285647 [Epub ahead of print]

Publisher's Disclaimer.

E-publishing ahead of print is increasingly important for the rapid dissemination of science. Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that have completed a regular peer review and have been accepted for publication.

E-publishing of this PDF file has been approved by the authors.

After having E-published Ahead of Print, manuscripts will then undergo technical and English editing, typesetting, proof correction and be presented for the authors' final approval; the final version of the manuscript will then appear in a regular issue of the journal.

All legal disclaimers that apply to the journal also pertain to this production process.

Challenges associated with access to recently developed hemophilia treatments in routine care: perspectives of healthcare professionals

Authors: Karin Berger¹, Roxy H. O'Rourke², Matteo Nicola Dario Di Minno³, Angelika Batorova⁴, Kaan Kavakli⁵, Pier Mannuccio Mannucci⁶, Wolfgang Schramm⁷, Rhonda L. Bohn⁸, Louis Aledort⁹ on behalf of the International Prophylaxis Study Group

¹Department of Medicine III, University Hospital, Ludwig-Maximilian University, Munich, Germany

²Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada

³Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy

⁴Faculty of Medicine of Comenius University and University Hospital, National Hemophilia Center, Department of Hematology and Transfusion Medicine, Bratislava, Slovakia ⁵Department of Haematology, Ege University Faculty of Medicine, Children's Hospital, Izmir, Turkey

⁶Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

⁷Ludwig-Maximilians University (LMU) Rudolf Marx Stiftung Munich, München, Germany

⁸Bohn Epidemiology, LLC, Boston, MA.

⁹Division of Hematology/Oncology, Icahn School of Medicine, Mount Sinai, New York, NY, United States of America

Corresponding Author:

Karin Berger, Department of Medicine III, Ludwig-Maximilian University Hospital, Munich, Marchionistrasse 15, Munich, Bavaria, 81377, Germany, email: karin.berger@med.uni-muenchen.de, phone: + 49(0) 89 440057435

Author Contributions: All authors designed the study. KB, RHO, and LA conducted data collection and analysis. KB, RHO, MDM, and LA wrote the initial draft of the manuscript. All authors reviewed the final manuscript.

Running title: Access to recent therapies in hemophilia

Funding: The International Prophylaxis Study Group Access Expert Working Group is a part of the broader International Prophylaxis Study Group (IPSG). The IPSG is a not-for-profit international collaborative study group whose mission is the acquisition of new knowledge regarding preventive care ('prophylaxis') for persons with inherited bleeding disorders and the dissemination of this knowledge globally. The IPSG is supported by independent education grants from Bayer Inc., BioMarin Pharmaceutical Inc, Novo Nordisk Healthcare AG, Pfizer, Sanofi, Sobi, and Takeda to the Hospital for Sick Children ("SickKids") Foundation in Toronto, Canada.

Acknowledgements

We would like to thank all individuals who assisted with the survey distribution and data collection in each of the respective countries included within the survey. We would like to acknowledge the ‘champions’ that assisted us with survey distribution, including, but not limited to: Dr. Gary Benson, Dr. Pratima Chowdary, Dr. Siobhan Cross, Dr. Niamh O’Connell, and Dr. Huyen Tran. This manuscript is a product of the Access Expert Working Group of the International Prophylaxis Study Group (the IPSPG).

Disclosures

Di Minno, M: research grants/personal honoraria – Bayer, SOBI, Pfizer, Bioviiiix, Novo-Nordisk, Roche, Takeda, CSL, Biomarin. Kavakli, K. personal honoraria/congress support/advisory board – Pfizer, Novo Nordisk, Roche, Sobi. Mannucci, P. M. personal honoraria – Roche, Takeda, Werfen and advisory board – Bayer Awards. Bohn, R. L. – founder of and Principal Epidemiologist at Bohn Epidemiology, LLC, consulting funds – clients in the pharmaceutical and biotechnology industry. There are no conflicts of interest with this manuscript. Berger, K., O’Rourke, R. H., Batorova, A., Schramm, W., and Aledort, L. declare no conflicts of interest.

Data Availability Statement: Data collected for this study will not be made available to others.

Abstract

The treatment landscape for haemophilia continues to rapidly develop, and expectations for future treatment success are high. There is limited information on the challenges to accessing new and innovative therapies. The aim of this study was to explore challenges with accessing haemophilia treatment from the perspective of healthcare professionals (HCPs). A cross-sectional study design was used. A pilot-tested, online survey was distributed to haemophilia treatment centres in Australia, Canada, France, Italy, New Zealand, Republic of Ireland, Turkey, the United States, and the United Kingdom. The questionnaire covered questions on product access, economic considerations, health technology assessment requirements, and patient organization involvement. The results were analyzed descriptively using SPSS. A total of 154 HCPs completed the questionnaire. There was heterogeneity across countries, regions, and centres regarding HCPs' knowledge of access to novel recently developed treatments. Notable limitations to access were reported such as differences in access based on age of patient and type of product, economic considerations, and the growing influence of HTA bodies. Many countries have a haemophilia patient organization that does not have a vote at the decision-making table. There is a need to empower HCPs to better understand national healthcare structures and decisions that lead to access limitations. Requirements from HTA bodies must be understood to optimally design clinical studies and value generation of treatment options. This may strengthen the haemophilia treatment centre's voice to collectively mandate for exchange with key involved individuals, such as the payers and politicians for the provision of optimal therapy.

Keywords: access, haemophilia treatment, health technology assessment, economics

Introduction

Hemophilia is a rare inherited bleeding disorder affecting more than 800,000 people, worldwide.¹ The condition can be life-threatening, with joint bleeding being the most common complication, which can result in major disability and mobility issues and, in turn, reduced quality of life.^{2,3} To prevent mortality and morbidity, in many regions, prophylactic treatment is the current standard of care, and discussions on its optimisation are ongoing.⁴ The landscape of recently developed novel therapeutic products, based on new mechanisms other than the replacement of deficient factor have progressed rapidly in recent years.⁵⁻⁷ There are several haemostatic therapies (e.g., enhanced half-life clotting factor concentrates, non-factor haemostatic therapies, and gene therapy) that are already in place or are about to enter the therapeutic landscape.⁸ These treatments, however, are cost intensive and not necessarily universally accessible.⁹⁻¹⁰ Due to high development costs, recently developed treatments are generally more expensive than standard treatments.^{5,11} Despite the significant improvements that have been afforded by the use of factor prophylaxis, many persons with haemophilia do not have access to such therapies (e.g., ~20% to 30% in low and middle income countries).¹²

For haemophilia healthcare providers, the primary goal of *access* is being able to receive optimal therapy for their patients. As recently developed treatments with the potential to greatly improve the clinical- and patient-reported outcomes of patients with haemophilia enter the therapeutic landscape, payers will require evidence on the added value and associated economic impact. A clear understanding of processes and evidence requested from decision makers is a prerequisite to minimize potential hurdles that limit access to recently developed therapies.^{13,14} In many countries, benefit and value (i.e., costs/outcomes) dossiers are required to be submitted for review by payers and/or health technology bodies (HTAs) before market launch. Information on potential benefits and harms of new treatments compared to available treatment options, which is often based upon these assessment processes and value demonstration, is taken into consideration when determining the reimbursement status and/or price negotiations of new therapies. The provision of requested evidence on benefits, based on scientific and pre-defined methodological requirements, is crucial for rare diseases, such as haemophilia.¹⁵ Despite a growing number of registries and other data sources, there is a lack of information on epidemiology, patient pathways, treatment patterns, and patient relevant outcomes for patients treated with standard of care haemophilia treatment, which is the basis for comprehensive value

ACCESS TO RECENTLY DEVELOPED THERAPIES IN HEMOPHILIA

assessments of recently developed treatments. Lastly, clinically relevant haemophilia treatment outcome measurements in clinical studies, and patient-reported outcome measurements, have to meet standards required by HTA bodies.^{16,17}

Due to recognized national and regional variabilities in access to haemostatic agents for use in persons with haemophilia, the objectives of this study were to understand healthcare providers' awareness of (i) which factors affect access to these recently developed treatments and (ii) whether access is limited due to lack of reimbursement or availability.

Methods

Design

A cross-sectional study design consisting of an internationally distributed survey was used. This study was granted ethics approval by The Hospital of Sick Children's institutional review board in September 2021.

Procedures

The questionnaire was developed through iterative rounds of review by clinical and health services research experts. The online questionnaire was distributed electronically through the Research Electronic Data Capture (REDCap®), a secure institutional data management system. The questionnaire was made available from December 2021 through November 2022.

Target countries of this initial survey of the IPSG Access EWG were selected based on having access to long-term prophylaxis within varying healthcare systems.¹⁸ As such, the following countries were selected based off this criterion, while also acknowledging feasibility and the exploratory nature of this work: Australia, Bulgaria, Canada, Croatia, Czech Republic, Estonia, France, Germany, Hungary, Italy, Lithuania, Latvia, Macedonia, New Zealand, Poland, Romania, Serbia, Slovakia, Slovenia, Turkey, UK and USA. To be eligible, while the survey was sent to haemophilia treatment centre directors, any staff member of the recognized registered haemophilia treatment centre could complete the questionnaire on behalf of that centre. The survey was available in English. Given it was an online survey, some individuals may have used an electronic translation platform to translate the webpage. No individuals indicated that the survey not being available in their country's primary or official language would be an issue, and no participants emailed the study coordinator indicating challenges in comprehension due to the survey only being available in English.

ACCESS TO RECENTLY DEVELOPED THERAPIES IN HEMOPHILIA

Survey distribution began with the involvement of local country ‘champions’ (i.e., a local haemophilia treater known by the research team). A member of the research team connected with the ‘champions’ in each country to determine the optimal method of survey distribution for each included country. Members of the IPSG were asked to identify a champion in their respective countries. The champions in the field of haemophilia were selected as first contacts within each of the selected countries. For many countries, clinicians holding key roles of local haemophilia organizations were selected. After an initial meeting with the ‘champion’, optimal methods for distributing the survey in their country were decided upon. Following the meeting, champions were asked to provide a list of all haemophilia treatment centres in their country along with the contact information of a lead physician working in each haemophilia treatment centre. Methods included having the local ‘champion’ distribute a letter introducing the survey to a member of each haemophilia treatment centre in the country, or the ‘champion’ provided the research team with an email list to distribute the survey to the local clinicians directly.

While there are no established cut-offs regarding ‘good’ or ‘acceptable’ response rates for surveys specific to healthcare providers, existing literature demonstrates response rates in physician surveys tend to be low. The response rate of our online survey is in the range of other published healthcare provider-specific surveys. A recently published review paper in *Annals of Surgery* titled “Global Overview of Response Rates in Patient and Health Care Professional Surveys in Surgery” presented an average response rate of 53% for web-based surveys.¹⁹ Another study on response rates for physician web-based surveys reported an overall response rate of 35% (42% internal medicine).²⁰ Outside of clinical research, the average response rate for online surveys is approximately 44%.²¹

Measures

Demographic characteristics were limited to job title of the respondent and haemophilia treatment centre characteristics (i.e., name of centre and type of patients followed at centre). The authors were aware of the discordance between products being licensed and their availability for access by patients. Therefore, the survey (see Supplementary Material) included questions on coverage of products and economic considerations (e.g., ‘In your country, who covers the expenses of haemostatic replacement therapies [factor and non-factor], including emicizumab outside of clinical trials?’), access to products and product restrictions (e.g., ‘Access to recently developed therapeutics is limited to certain indications’), ethical issues experienced (e.g., ‘Please

ACCESS TO RECENTLY DEVELOPED THERAPIES IN HEMOPHILIA

provide any ethical issues that may influence how you prescribe factor [e.g., cost]'), health technology assessment bodies (e.g., 'Does the HTA body in your country have a well-defined and transparent process in terms of methodological requirements and assessment methods for recommending/approving reimbursement of haemophilia treatments?'), and the presence and role of haemophilia patient organizations for access (e.g., 'Does the patient organization have a vote at the decision making table regarding the funding for a haemostatic agent that has regulatory approval and support from a formal HTA or equivalent?'). Response options varied depending on the question, including yes/no/I don't know options, ranking from 1 'most important' to 4 'least important', multiple choice responses, open-ended responses, as well as a Likert scale ranging from strongly agree to strongly disagree.

Statistical Analysis

Data were analyzed using SPSS software version 29.0. Descriptive statistics of the sample, including frequencies and percentages, for each survey question were computed. As indicated previously, the data from countries with few responses were excluded from the analysis due to the small sample sizes. The reporting of the survey results follows the Checklist for Reporting Results of Internet E-Surveys (CHERRIES).²²

Results

As shown in Table 1, the survey was distributed to 377 healthcare providers (HCPs) and a total of 154 complete responses were collected (overall response rate 40.8%). Countries that were included, as well as those recruited but not included within the data analysis due to a low response rate are provided in Table 1. Specifically, 78% (n=120) of responses were from countries where mainly government health agencies pay for haemophilia therapies, compared to a heterogeneous funding system in the United States of America (USA; 21.4%, n=33) and Turkey (0.6%, n=1). Out of 154 HTCs, 29 had only pediatric patients, 26 had only adults and 99 reported both pediatric and adult patients.

The results were summarized into four categories that highlight the challenges the included countries are facing in terms of access to recently developed haemophilia treatments: (1) differences in access based on age of patient and type of product, (2) economic considerations and cost of products influence access, (3) lack of transparency of the HTA recommendation and approval process for treatment reimbursement, and (4) the role of the haemophilia patient organization.

ACCESS TO RECENTLY DEVELOPED THERAPIES IN HEMOPHILIA

Differences in access based on age of patient and type of product

Many respondents (119 HCPs, 77.3%) reported that, from their perspectives, access to products, in general, was the same for both adults and children. A total of 12 (8%) respondents reported that they perceived access was greater for adults, and 17 (11%) respondents reported that access was greater for children (See Figure 1).

As shown in Figure 2, a total of 98 HCPs (64%) reported that access to recently developed therapies (e.g., extended half-life [EHL] FVIII/FIX, non-factor therapy [i.e., emicizumab], and/or gene therapy) was limited to certain indications. This was reported by the majority of respondents from Canada (91%, n=20/22), Italy (63%, n=17/27), New Zealand (100%, n=6/6), Turkey (65%, n=11/17), England (63%, n=10/16), Northern Ireland (50%, n=1/2), Scotland (100%, n=2/2), Wales (50%, n=1/2), and the USA (61%, n=20/33). Specifically, 54 HCPs (35%) and 47 HCPs (31%) reported limited access to EHL-FVIII and EHL-FIX, respectively. The highest percentage of respondents who agreed or strongly agreed with this statement of limited access to EHL was from Turkey (59%, n=10/17). Additionally, 76 HCPs (49%) reported limited access to non-factor therapies, including 100% of HCPs from New Zealand (n=6/6) and Northern Ireland (n=2/2). Lastly, 74 HCPs (48%) reported limited access to gene therapy, including 100% of HCPs from Northern Ireland (n=2/2).

Economic considerations and cost of products influence access

Overall, 62 HCPs (40%) 'agreed' there are existing situations in routine care where economic considerations impact therapeutic choices of the treating physician (See Figure 3). Additionally, 69 HCPs (44.8%) reported that the price of haemostatic agents (factor and non-factor) outside of clinical trials influences access to treatment (See Figure 4). The impact of price of products influencing access was largely reported amongst HCPs from Canada (59.1%, n=13/22), New Zealand (66.7%, n=4/6), Turkey (52.9%, n=9/17), England (62.5%, n=10/16), and the USA (60.6%, n=20/33).

Lack of transparency of the HTA recommendation and approval process for treatment reimbursement

Most countries included have a national HTA body, or equivalent, that is responsible for evaluating new drugs and treatments, and most of these respondents (90.08%, n=109/121) reported they were *aware* of the national HTA body in their country. Of those with an HTA or equivalent, many respondents (79.44%, n=85/107) reported the HTA body in their country has a

ACCESS TO RECENTLY DEVELOPED THERAPIES IN HEMOPHILIA

well-defined and transparent process in terms of methodological requirements and assessment methods for recommending and approving reimbursement of haemophilia treatments. Some, however, reported the HTA body does not have (8.41%, n=9/107), or did not know if the HTA body has (12.15%, n=13/107), a well-defined or transparent process (See Figure 5). Evaluating the type of evidence used as a driver in the benefit assessment for reimbursement recommendations or decisions of haemophilia treatments in each included country, randomized controlled trials were scored as the most important by 76 HCPs (49.3%). Besides randomized controlled trials, real-world evidence and systematic literature reviews were scored as the most important evidence used as a driver in the benefit assessment for reimbursement recommendations/decisions of haemophilia treatments by 13 HCPs (8.4%) and 6 HCPs (3.9%), respectively. In evaluating the type of health economic aspects considered by the HTA, 95 HCPs (61.7%) reported cost-effectiveness analysis and 60 HCPs (38.9%) reported budget impact analysis. More specifically, a total of 66 HCPs (42.9%) confirmed that budget impact analyses of new haemophilia treatments are requested by payers of haemostatic therapies in their country.

The role of the haemophilia patient organization

Most HCPs (97.4%, n=150) reported the presence of a hemophilia patient organization within their country. Additionally, 123 HCPs (79.9%) reported that the hemophilia patient organizations lobby for access. Despite having a presence and lobbying for access, only 29 HCPs (18.8%) reported these haemophilia patient organizations have a vote at the decision-making table regarding the funding for a haemostatic agent that has regulatory approval and support from a formal HTA or equivalent (See Figure 6).

Discussion

This survey is one of the first in the field of haematology to address the awareness of access to recently developed treatments from the HCP's perspective. The topic of access, specifically concerning recently developed treatments, from the viewpoint of the HCP is an identified gap of knowledge in the literature. Seeking the subjective opinions of HCPs who work with patients with chronic health conditions, such as bleeding disorders, is crucial to identify timely challenges and perceptions regarding access to resources. Without the HCP's perspective, there are limitations in enhancing infrastructure, bettering patient interactions, as well as improving clinical- and patient-reported outcomes, such as health-related quality of life. As the landscape of recently developed innovative treatments with promising clinical- and patient-

ACCESS TO RECENTLY DEVELOPED THERAPIES IN HEMOPHILIA

reported outcomes for persons with haematological diseases has progressed rapidly in recent years, we used haemophilia as a use case for a rare haematological disorder. This survey serves as a temperature check to assess HCP's awareness, experiences, and perceptions of access to optimal haemophilia treatment in their daily routine care.¹⁸

The results demonstrate that a majority of the respondents are aware about access in their respective countries. However, it has to be highlighted that the variation and heterogeneity of knowledge on access was evident, both between and within countries. Further, findings indicated that, in most of the included countries, there are added barriers to optimal access to haemophilia treatment (e.g., differences in access based on age of patient and type of product or certain indications). As such, there may be a need to generate more information on the topic of access to newly licenced therapies in routine care. In addition, the findings highlight a need to empower HCPs to understand and observe national healthcare structures that lead to limitations in access to optimal therapy. This can potentially empower HTCs to collectively take a mandate for the provision of optimal therapy. This is in contrast to clinical trials for which multinational trials are the standard, where access to therapies, especially those expensive, is limited by the structures and processes of the respective national healthcare systems.

The results of the survey demonstrate the need to know about requirements of established HTA processes, or their equivalent, which are an add-on to established licencing and approval processes. In the centre of most HTA processes is the value assessment for decision making regarding reimbursement, primarily from the payer's perspective. Although a drug may be licensed, it does not guarantee subsequent access. If the value assessment does not demonstrate the added value of a new drug, payers will not be willing to reimburse premium prices. Therefore, despite a drug being licensed, no reimbursement from the payers contributes to a limitation in access for patients. Within this survey, 90% of respondents reported being from a country with an HTA body, or equivalent. Of these respondents, 80% reported that the HTA body in their country has a well-defined and transparent process for recommending and approving reimbursement of haemophilia treatments. When evaluating the type of evidence used as a driver in the benefit assessment for reimbursement recommendations or decisions of haemophilia treatments, 50% of respondents reported randomized controlled trials to be the most important. Therefore, following recommendation number 11 of the Wildbad Kreuth Initiative, which specifies that "clinical studies should be performed to provide the best possible evidence

ACCESS TO RECENTLY DEVELOPED THERAPIES IN HEMOPHILIA

needed for regulatory authorities, health technology assessment (HTA) bodies, academia and healthcare providers”, clinical trial designs for recently developed therapies are recommended.²³ Clinical trial designs will help to reduce bias, lower financial costs, and improve patient access through providing evidence to promote effective HTA and cost-effectiveness analyses.

The relevance of health economic analyses in terms of cost-effectiveness and budget impact was also emphasised in the findings of this survey. Approximately 40% of HCPs ‘agreed’ that there are existing situations in routine care where economic considerations impact therapeutic choices of the treating physician, with the price of a drug seeming to be an important decision criterion. In Germany, a prior survey among hematologists reported comparable findings.²⁴

The reason for treatment decisions with consideration of prices may be manifold, such as internal requirements from the administrative side of the respective institution, complex application processes, expected disputes with the payers for reimbursement, as well as too little transparency and trust in the expected outcomes. However, if those rationing decisions are neither guided by a consensus on what should count as dispensable benefit nor shared with the patient, there is a high likelihood that patients in similar clinical situations will receive different care solely because of the physicians they encounter in the course of their illness. Future research on the reasoning behind decisions made around use of costly treatments, and the associated impact on patient outcomes, is needed. Based on the findings of this study, the field may benefit from a systematically and transparently developed process for engaging all roles involved in the drug licensing, value assessment, and care process to avoid individualized institutional rationing.²⁵

A majority also reported that the haemophilia patient organizations present in their country lobby for access, but only a minority reported that these haemophilia patient organizations have a vote at the decision making table. Patients and patient organizations have much to contribute to the decision making process as a result of their lived experiences, therefore, patients must be involved within decision making on new treatments. Despite various efforts in the field of rare diseases, such as the discussions in the policy-engagement workshop in Edinburgh 2026,²⁶ and initiatives of the World Federations of Haemophilia and European Consortium it seems that, according to the present survey results, further and continuous efforts,

ACCESS TO RECENTLY DEVELOPED THERAPIES IN HEMOPHILIA

especially national ones, are important to give patients an active voice in decision making processes where this is not yet a reality.

There are a few minor limitations of this survey to note. The representativeness of the survey is limited. While a response rate for each country's respondents could be calculated, we are limited in our ability to state that the findings at the country level are representative of that country's access. To build on the needs and challenges identified in this exploratory study, confirmatory research at the national/international level that includes the perspectives of different types/levels of healthcare providers as well as, importantly, patient representatives, should be a priority within national research agendas. For this kind of research, country specific representativeness will be essential. Additionally, the proportion of different professional groups that provided feedback within each country varied and might lead to an information bias. This is based, among other things, on the different structures of the health systems. Lastly, the countries included within this study are classified as upper-middle- and high-income countries according to the World Bank.²⁷ While the focus on upper-middle- and high-income countries allowed for some cross-country comparisons to be made within this study. We observed variations in access between the included economically wealthier countries. Future research is needed with representatives from lower-middle- and low-income countries to further understand differences, and barriers, to access.

In summary, these findings can inform HCPs, manufacturers, and patients alike. Here, we highlight the key takeaways from the findings of the survey. There is a large amount of heterogeneity across the included countries, regions, and centres regarding HCPs' knowledge of access. Access to innovative haemophilia therapy is determined by national conditions of the healthcare system in the respective country. This paper provides initial cross-national evidence on access to recently developed haematological therapies from the HCP's perspective. Therefore, the value of the findings from this comprehensive survey is the knowledge that there are notable limitations to access and the need to better understand requirements from HTA bodies to optimally design clinical studies and to provide evidence for the value of different treatment options.

Knowledge gaps regarding access from the HCP perspective should be filled in future work through providing more information, education, and empowerment. There is a need to empower HCPs to understand and observe national healthcare structures in the context of other

ACCESS TO RECENTLY DEVELOPED THERAPIES IN HEMOPHILIA

countries that lead to limitations in access to optimal therapy. Potential avenues for doing so include trainings and discussion exchange platforms geared towards initiating conversations with decision makers external to the medical area. This can potentially empower HTCs to collectively mandate for exchange with key individuals, such as the payers and politicians for the provision of optimal therapy. Importantly, patient advocacy groups, while involved in conversations on access, are not involved in decision making processes on access to treatment. Finally, the generated evidence corroborates the need for more interprofessional health services research, outcomes research, and health economics as complements to basic research for access to optimal haemophilia care. National HTCs should be empowered with information and consensus papers to initiate a dialogue with other key roles, such as agencies, academia, payers, and patients to foster access to optimal haemophilia treatment.

References

- [1] Stonebraker JS, Bolton Maggs PH, Brooker M, et al. The World Federation of Hemophilia annual global survey 1999–2018. *Haemophilia*. 2020;26(4):591-600.
- [2] Elsafy OR, Mohammed MA, Abdelfatah NR, Ishtaiwi IE. Impact of hemophilia on health-related quality of life in pediatric population. *Egypt J Hosp Med*. 2021;85(1):3047-3412.
- [3] von Mackensen S, Gringeri A. Quality of life in hemophilia. In: Lee CA, Bernortorp EE, Hoost WK. *Textbook of Hemophilia*. John Wiley & Sons, Ltd; 2014. p. 478-488.
- [4] Bernortorp E, Hermans C, Solms A, Poulsen L, Mancuso ME. Optimising prophylaxis in haemophilia A: the ups and downs of treatment. *Blood Rev*. 2021;50:100852.
- [5] Mannucci PM. Hemophilia treatment innovation: 50 years of progress and more to come. *J Thromb Haemost*. 2023;21(3):403-412.
- [6] Peyvandi F, Garagiola I, Young G. The past and future of haemophilia: diagnosis, treatments, and its complications. *Lancet*. 2016;388(10040):187-197.
- [7] Weyand AC, Pipe SW. New therapies for hemophilia. *Blood*. 2019;133(5):389-398.
- [8] Gogia P, Tarantino M, Schramm W, Aledort L. New directions to develop therapies for people with hemophilia. *Expert Rev Hematol*. 2023;16(6):417-433.
- [9] Ghosh K, Ghosh K. Overcoming the challenges of treating hemophilia in resource-limited nations: a focus on medication access and adherence. *Expert Rev Hematol*. 2021;14(8):721-730.
- [10] Pelland-Marcotte MC, Carcao MD. Hemophilia in a changing treatment landscape. *Hematol Oncol Clin North Am*. 2019;33(3):409-423.
- [11] Rodriguez-Merchan EC. The cost of hemophilia treatment: the importance of minimizing it without detriment to its quality. *Expert Rev Hematol*. 2020;13(3):269-274.
- [12] Ghosh K, Ghosh K. Management of haemophilia in developing countries: challenges and options. *Indian J Hematol Blood Transfus*. 2016;32(3):347-355.
- [13] Ten Ham RM, Walker SM, Soares MO, et al. Modeling benefits, costs, and affordability of a novel gene therapy in hemophilia A. *Hemasphere*. 2022;6(2):e679.
- [14] Thorat T, Neumann PJ, Chambers JD. Hemophilia burden of disease: a systematic review of the cost-utility literature for hemophilia. *J Manag Care Spec Pharm*. 2018;24(7):632-642.
- [15] O'Mahony B, Wong O, Eichler H, Neumann P, Carlsson KS, Noone D. Preparing for tomorrow: defining a future agenda. *Haemophilia*. 2022;28 Suppl 2:35-41.

ACCESS TO RECENTLY DEVELOPED THERAPIES IN HEMOPHILIA

[16] O'Hara J, Neumann PJ, International Haemophilia Access Strategy Council. Health technology assessment for gene therapies in haemophilia. *Haemophilia*. 2022;28 Suppl 2:19-26.

[17] Skinner MW, Dolan G, Eichler H, O'Mahony B, International Haemophilia Access Strategy Council. A preliminary application of a haemophilia value framework to emerging therapies in haemophilia. *Haemophilia*. 2022; 2022;28 Suppl 2:9-18

[18] Berger K, Batarova A, Bohn R, et al. Are all licensed haemostatic agents for haemophilia therapy accessible to patients?. *Haemophilia*. 2022;28(6):e256-e258.

[19] Meyer VM, Benjamens S, El Moumni M, Lange JF, Pol RA. Global overview of response rates in patient and health care professional surveys in surgery: a systematic review. *Ann Surg*. 2022;275(1):e75-e81.

[20] Cunningham CT, Quan H, Hemmelgarn B, et al. Exploring physician specialist response rates to web-based surveys. *BMC Med Res Methodol*. 2015;15:32.

[21] Wu MJ, Zhao K, Fils-Aime F. Response rates of online surveys in published research: a meta-analysis. *Comput Hum Behav Rep*. 2022;7:100206.

[22] Eysenbach G. Improving the quality of Web surveys: the Checklist for Reporting Results of Internet E-Surveys (CHERRIES). *J Med Int Res*. 2004;6(3):e34.

[23] Peyvandi F, Berger K, Seitz R, et al. Kreuth V initiative: European consensus proposals for treatment of hemophilia using standard products, extended half-life coagulation factor concentrates and non-replacement therapies. *Haematologica*. 2020;105(8):2038-2043.

[24] Krause SW, Schildmann J, Lotze C, Winkler EC. Rationing cancer care: a survey among the members of the German Society of Hematology and Oncology. *J Natl Compr Canc Netw*. 2013;11(6):658-665.

[25] Moosa MR, Luyckx VA. The realities of rationing in health care. *Nat Rev Nephrol*. 2021;17(7):435-436.

[26] Mikami K, Sturdy S. Patient organization involvement and the challenge of securing access to treatments for rare diseases: report of a policy engagement workshop. *Res Involv Engagem*. 2017;3:14

[27] Metreau E, Young KE, Eapen SG. World Bank country classifications by income level for 2024-2025. *World Bank Blogs*. Accessed July 11, 2024.

<https://blogs.worldbank.org/en/opendata/world-bank-country-classifications-by-income-level-for-2024-2025>

Tables**Table 1.** Survey distribution and completion by country.

| Country | Distributed (N) | Completed Responses (N) | Response Rate (%) |
|-----------------------------|--------------------|----------------------------|----------------------|
| Included Respondents | | | |
| Australia | 17 | 12 | 70.6% |
| Canada | 34 | 22 | 64.7% |
| France | 30 | 10 | 33.3% |
| Italy | 51 | 27 | 52.9% |
| New Zealand | 6 | 6 | 100.0% |
| Republic of Ireland | 4 | 5 ^a | 125.0% |
| Turkey | 40 | 17 | 42.5% |
| UK | 33 | 22 | 66.7% |
| United States | 162 | 33 | 20.4% |
| Excluded Respondents | | | |
| Germany | 80 | 5 | 6.3% |
| Bulgaria | 3 | 0 | 0% |
| Croatia | 2 | 0 | 0% |
| Czech Republic | 10 | 1 | 10.0% |
| Hungary | 4 | 1 | 25.0% |
| Estonia | 3 | 0 | 0% |
| Lithuania | 2 | 0 | 0% |
| Latvia | 2 | 0 | 0% |
| Poland | 5 | 0 | 0% |
| Romania | 2 | 0 | 0% |
| Slovakia | 5 | 1 | 20.0% |
| Slovenia | 2 | 1 | 50.0% |
| Macedonia | 1 | 0 | 0% |
| Serbia | 2 | 0 | 0% |

^a Two individuals completed the survey at one centre. Given the survey asked the healthcare providers' perspectives of access, there were variations in the responses between these two survey responses, and the research team deemed it was not appropriate to select the 'better' response. Because of this, both survey responses were included, and the number of responses is one greater than the total number of centres.

Figure Captions

Figure 1. Age-related differences in access to hemostatic agents at the respondents' hemophilia treatment centres.


Figure 2. Access to innovative therapies is limited to certain indications.

Figure 3. There are existing situations in routine care where economic considerations impact therapeutic choices.


Figure 4. Does price of hemostatic agents (factor and non-factor) outside of clinical trials influence the access to treatment?


Figure 5. Does the health technology assessment body have a well-defined and transparent process in terms of methodological requirements and assessment methods for recommending/approving reimbursement of hemophilia treatments?


Figure 6. Does the patient organization have a vote at the decision making table regarding the funding for a hemostatic agent that has regulatory approval and support from a formal health technology assessment or equivalent?





- I don't know
- Greater for children <18 years
- Greater for adults
- The same for both adults and children <18 years











Supplemental Materials

IPSG Access Survey

General Information

- Email address
- Job profile (e.g., adult hematologist, hemophilia treatment centre medical director)
- Name of hemophilia treatment centre
- What type of patients are followed at your HTC?
 - Pediatrics (< or =18 years)
 - Adults (>18 years)
 - Adults and pediatrics

Survey Questions

1. In what country are you currently practicing or working: _____
2. Who covers the expenses of hemophilia care in your country?
 - a. Public insurance (government)
 - b. Private insurance companies
 - c. Patient only
 - d. Other only
 - i. Please specify: _____
 - e. Combination of any of the above (please estimate proportion of coverage)
 - i. Public insurance: _____ %
 - ii. Private insurance: _____ %
 - iii. Patient: _____ %
 - iv. Other: _____ %
 - v. I don't know: _____ %
3. In your country, does the price influence access to treatment?
 - a. Yes
 - b. No
 - c. I don't know
4. In your country, is access to hemostatic agents:
 - a. The same for both adults and children < 18 years
 - b. Greater for adults
 - c. Greater for children < 18 years
 - d. I don't know
5. Comments on product restrictions (e.g., Pegylated FVIII/IX products may not be approved by a national body such as the FDA/EMA for use in boys with hemophilia < 12 years of age): _____
6. Please select one answer for each of the following statements below:

*Enhanced half-life (EHL) clotting factor concentrates, non-factor treatment, gene therapy

| | Strongly Disagree | Disagree | Neither Agree nor Disagree | Agree | Strongly Agree |
|---|-------------------|----------|----------------------------|-------|----------------|
| There are existing situations in routine care where economic considerations impact your therapeutic choices | | | | | |
| Access to innovative therapeutics* is limited to certain indications | | | | | |
| EHL-FVIII | | | | | |
| EHL-FIX | | | | | |
| Non-factor hemostatic therapies | | | | | |
| Gene therapy | | | | | |
| There are haemophilia drugs you would like to prescribe but they are not available | | | | | |
| You are adequately informed about the relation of costs and benefits of your therapeutic recommendations | | | | | |
| Patients/families (e.g., parents/guardians) are currently more involved in the shared decision making regarding the use of innovative therapies for treatment | | | | | |

7. If you agree that access is limited to certain indications, please provide any ethical issues that may influence how you prescribe factor (e.g., cost): _____

The following list of questions relate. To documents to be submitted to payers or Health Technology Assessment bodies (HTA) for reimbursement of new therapies and treatments for haemophilia.

8. Is there a national HTA (Health Technology Assessment) body or equivalent in your country whose responsibility is to evaluate new drugs and treatments? (e.g., CADTH)
- Yes
 - No
 - I don't know
9. Please indicate the name of the HTA body in your country/region (select all that apply).
- Government
 - Institution
 - Other
 - I don't know

10. If Government, please specify the name of the body: _____

11. If Institution, please specify the name of the body: _____

12. If Other, please specify the name of the body: _____

13. Does the HTA body in your country have a well-defined and transparent process in terms of methodological requirements and assessment methods for recommending/approving reimbursement of hemophilia treatments?

- a. Yes
- b. No
- c. I don't know

14. What type of evidence is the strongest driver in benefit assessment for reimbursement recommendations/decisions in your country? Please rank the items below from 1 to 4 (1 – Most Important and 4 – Least Important).

| | 1 | 2 | 3 | 4 |
|--|---|---|---|---|
| Randomized controlled trials (RCT) | | | | |
| Real world data (RWD) (e.g., registry, longitudinal observational studies) | | | | |
| Systematic literature review | | | | |
| Other | | | | |

15. If “Other” type of evidence, please specify: _____

16. What type of health economic aspects are part of the HTA?

- a. Cost-effectiveness analyses
- b. Budget impact analysis
- c. I don't know

17. Are budget impact analyses of new hemophilia treatments requested by payers of hemostatic therapies in your country?

- a. Yes
- b. No
- c. I don't know

18. Is there a hemophilia patient organization in your country/region?

- a. Yes
- b. No
- c. I don't know

19. Does this organization lobby for access?

- a. Yes
- b. No
- c. I don't know

20. Does the patient organization have a vote at the decision-making table regarding the funding for a hemostatic agent that has regulatory approval (i.e., Health Canada/FDA/EMA, etc.) and support from a formal Health Technology Assessment or equivalent?
- a. Yes
 - b. No
 - c. I don't know
21. Are there any comments you would like to share with us that are relevant to access to hemostatic therapies for the use and prevention of bleeding in persons with hemophilia and other severe inherited bleeding disorders registered and followed in your hemophilia treatment centre: _____
22. Please provide any comments and/or suggested revisions you may have regarding the IPSPG Access Survey: _____